查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2003200

進行性遺傳性肝內膽汁淤積症 (PFIC) 治療市場：2026 年至 2032 年全球市場預測（按治療方法、藥物類別、給藥途徑、患者年齡層、PFIC 類型、最終用戶和配銷通路分類）

Progressive Familial Intrahepatic Cholestasis Treatment Market by Treatment Type, Drug Class, Route Of Administration, Patient Age Group, PFIC Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，進行性遺傳性肝內膽汁淤積症 (PFIC) 的治療市場價值將達到 1.244 億美元，到 2026 年將成長到 1.2987 億美元，到 2032 年將達到 1.7281 億美元，複合年成長率為 4.80%。

主要市場統計數據
基準年 2025 1.244億美元
預計年份：2026年 1.2987億美元
預測年份 2032 1.7281億美元
複合年成長率 (%) 4.80%

為提供 PFIC 護理的臨床、治療和操作背景的簡明權威概述，並明確所有相關人員。

進行性遺傳性肝內膽汁淤積症（PFIC）是一組遺傳和臨床表現各異的膽汁淤積性肝病，在診斷、臨床治療和長期照護的各個階段都面臨著複雜的挑戰。患者自嬰兒早期起便出現進行性肝功能障礙，通常需要藥物治療、支持性治療以及在許多情況下需要手術介入的綜合治療方案。因此，臨床醫生、研究人員和醫療保健系統正在尋求多管齊下的策略，以平衡短期症狀控制和從根本上改變疾病發病機制的長期治療方案。

新的治療方法、適應性監管方法和綜合護理模式的融合正在重新定義 PFIC（生理性精神感染）的治療範式和引入途徑。

近年來，科學、監管和醫療服務等多面向因素的共同作用，為進行性家族性肝內膽汁淤積症（PFIC）領域帶來了變革性的變化。分子遺傳學的進步和對膽汁酸生理學更深入的理解，加速了標靶藥物療法的研發，這些藥物能夠直接調節腸肝循環。這項發展使得治療選擇不再局限於緩解症狀的支持性療法，而是擴展到能夠改變疾病進程、延緩甚至避免侵入性手術干預的藥物。

本研究評估了美國計劃於 2025 年實施的關稅措施對 PFIC 治療的供應鏈、臨床項目、採購和患者獲取途徑的影響。

美國近期宣布的2025年關稅措施，透過影響跨境供應鏈的經濟和物流環節，為被動真菌感染（PFIC）治療生態系統帶來了新的複雜性。許多特種藥品、原料和生物製藥都依賴國際生產和分銷網路。隨著關稅增加活性成分、成品或輔助設備的採購成本，贊助商和經銷商將面臨重新評估籌資策略、庫存管理以及與生產合作夥伴的合約條款的壓力。

整合細分情報，揭示治療類型、藥物分類、醫療保健環境、分銷管道、途徑、年齡層和 PFIC 亞型如何影響策略和實施。

在進行性家族性肝內膽汁淤積症 (PFIC) 的治療過程中，由於治療方案涉及不同的治療分類、臨床環境和患者群體，因此，以患者群體為導向的決策對於個性化開發和商業化至關重要。就治療類型而言，藥物治療是緩解疾病和症狀管理臨床策略的核心，其中膽汁酸吸附劑和髂骨膽汁酸轉運體抑制劑作為標靶機制尤為重要。在藥物治療中，膽汁酸吸附劑（如考來烯胺和考來維崙）在緩解症狀和改善生化指標方面發揮作用，而迴腸膽汁酸轉運體抑製劑（如馬拉利昔瓦和奧德比昔瓦）旨在減少毒性膽汁酸的積累。利福平和熊去氧膽酸等輔助治療藥物在緩解症狀和改善生化指標方面也仍然十分重要。支持治療仍然至關重要，營養支持和症狀管理對於維持生長和生活品質至關重要。同時，從膽道旁路手術到肝臟移植等外科手術，為難治性或進行性疾病的逐步升級治療提供了選擇。

美洲、歐洲、中東、非洲和亞太地區在臨床網路、支付方框架和醫療保健基礎設施方面的區域差異正在影響醫療服務的取得和採用趨勢。

區域趨勢對進行性家族性肝內膽管炎（PFIC）治療方法的研發、實施和報銷有顯著影響，美洲、歐洲、中東、非洲和亞太地區之間存在顯著差異，進而影響臨床實踐模式和治療途徑。在美洲，集中化的高品質醫療中心、完善的移植網路和成熟的專科藥房管道為新治療方法的早期應用提供了支持。然而，保險公司越來越要求提供可靠的真實世界數據和長期療效數據，以證明高昂治療費用的合理性。在此背景下，能夠證明患者獲益清晰，並建立包含移植項目和兒童肝病中心在內的綜合診療路徑的申辦方將更具優勢。

創新公司、專業製藥公司和臨床網路如何協調其研發、夥伴關係和商業策略，以塑造其在 PFIC 領域的競爭地位和市場接受度？

在PFIC（持續性、功能性、免疫和免疫）領域，專業化、策略夥伴關係和適應性商業化策略是企業競爭定位的關鍵要素。開發標靶治療的創新公司通常與臨床中心和學術網路合作，設計臨床試驗，以捕捉諸如瘙癢減輕、生化指標改善和非移植生存率等有意義的終點指標。專業製藥公司和生物製藥開發公司透過製劑科學、適合兒童的給藥途徑以及滿足監管機構和支付方需求的數據生成計劃來脫穎而出。同時，醫療服務提供者和移植中心在支持協作式照護路徑方面發揮越來越重要的策略作用，這些路徑有助於建立登記系統、追蹤長期療效並引入新的治療方法。

採取切實有效的領導行動，協調證據產生、供應彈性和商業策略，以加速 PFIC治療方法的引入並改善患者預後。

產業領導者必須採取一系列合作措施，以確保PFIC領域的科學進步能夠轉化為永續的臨床和商業性影響。首先，研發項目應優先考慮能夠反映患者真實體驗和長期器官保存情況的終點指標，並使試驗設計與支付方的證據需求保持一致。其次，申辦方應儘早投資於真實世界資料平台和病患登記系統，以便將臨床試驗資料與長期療效聯繫起來，並為醫保報銷談判和核准後監測提供支援。

採用嚴謹的混合方法，結合關鍵相關人員的訪談、臨床文獻的整合和情境分析，檢驗了對 PFIC相關人員。

本研究採用多方法整合策略，旨在融合臨床專業知識、相關人員的觀點以及同儕審查文獻的證據。主要研究包括對臨床醫生、移植外科醫生、專科藥劑師和支付方代表進行結構化訪談，以了解治療方法選擇、物流供應和報銷方面的實際考慮。這些定性資訊被用於對近期臨床文獻進行系統性回顧和檢驗，以識別PFIC研究中使用的新型治療機制、相關安全考量和試驗終點。

策略整合突顯了將治療創新轉化為 PFIC 患者療效的永續改善所必需的條件和協作努力。

在科學進步、不斷發展的醫療模式和不斷變化的經濟限制因素的推動下，進行性膽汁淤積性肝病 (PFIC) 的治療格局正處於轉折點。標靶調節膽汁酸代謝的療法、完善的多學科診療網路以及適應性強的監管流程共同作用，為改善進行進行性膽汁淤積性肝病患者的預後創造了機會。然而，實現這些益處需要各方通力合作：一方面需要提供強力的證據以贏得監管機構和支付方的認可；另一方面需要製定供應鏈策略以降低外部風險；此外，還需要製定能夠反映終端用戶需求和當地醫療體系特點的精準商業化計劃。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：進行性遺傳性肝內膽汁淤積症（PFIC）治療市場（依治療方法分類）

  • 藥物治療
    • 抗生素
    • 膽汁酸吸附劑
      • 考來烯胺
      • 核心
    • IBAT抑制劑
      • 馬拉利希巴特
      • 奧德比·基斯巴特
    • 利福平
    • 熊去氧膽酸
  • 支持性護理
    • 營養支持
    • 症狀管理
  • 手術介入
    • 膽道繞道手術
    • 肝臟移植

第9章：進行性遺傳性肝內膽汁淤積症（PFIC）治療市場：依藥物類別分類

  • 抗生素
  • 膽汁酸吸附劑
    • 考來烯胺
    • 核心
  • IBAT抑制劑
    • 馬拉利西巴特
    • 奧德比·基斯巴特
  • 熊去氧膽酸

第10章：進行性遺傳性肝內膽汁淤積症（PFIC）治療市場：依給藥途徑分類

  • 靜脈
  • 口服

第11章 依病患年齡層別分類的進行性遺傳性肝內膽汁淤積症 (PFIC) 治療市場

  • 青年
  • 成人
  • 兒童

第12章進行性遺傳性肝內膽汁淤積症 (PFIC) 治療市場（按 PFIC 類型分類）

  • 一型
  • II 型
  • III型

第13章：進行性遺傳性肝內膽汁淤積症（PFIC）治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第14章：進行性遺傳性肝內膽汁淤積症（PFIC）治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章：進行性遺傳性肝內膽汁淤積症（PFIC）治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：進行性遺傳性肝內膽汁淤積症（PFIC）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章進行性遺傳性肝內膽汁淤積症（PFIC）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國進行性遺傳性肝內膽汁淤積症（PFIC）進行性市場

第19章：中國進行性遺傳性肝內膽汁淤積症（PFIC）進行性市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie, Inc.
  • Albireo Pharma, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Limited
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mirum Pharmaceuticals, Inc.
  • Novartis International AG
  • Par Pharmaceutical Companies, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-AD517FAAA5F2

The Progressive Familial Intrahepatic Cholestasis Treatment Market was valued at USD 124.40 million in 2025 and is projected to grow to USD 129.87 million in 2026, with a CAGR of 4.80%, reaching USD 172.81 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 124.40 million
Estimated Year [2026] USD 129.87 million
Forecast Year [2032] USD 172.81 million
CAGR (%) 4.80%

A concise and authoritative overview of the clinical, therapeutic, and operational context for PFIC care that frames strategic priorities across stakeholders

Progressive familial intrahepatic cholestasis (PFIC) represents a set of genetically and clinically heterogeneous cholestatic liver disorders that present complex challenges across diagnosis, clinical management, and long-term care. Patients encounter progressive liver dysfunction from early life onward, often requiring a mix of pharmacologic approaches, supportive interventions, and in many cases surgical procedures. Clinicians, researchers, and health systems are therefore pursuing multimodal strategies that balance immediate symptom control with durable approaches that alter disease biology.

This executive summary frames the contemporary landscape for PFIC treatment by synthesizing developments across therapeutic modalities, regulatory pathways, and care delivery models. It highlights the drivers reshaping clinical priorities, such as new targeted agents designed to reduce intrahepatic bile acid burden, evolving standards for liver transplantation and diversion procedures, and the maturation of specialist care networks. The narrative also emphasizes the importance of aligning clinical innovation with supply chain resilience, payer engagement, and patient-centered care models to ensure that advanced therapies translate into equitable real-world benefit. By setting this context, the introduction prepares the reader for a deeper exploration of transformative shifts, segmentation intelligence, regional considerations, and tactical recommendations aimed at stakeholders across the therapeutic ecosystem.

Emerging therapeutic innovations, adaptive regulatory approaches, and integrated care models converging to redefine treatment paradigms and adoption pathways for PFIC

Over the last several years, a confluence of scientific, regulatory, and care-delivery forces has produced transformative shifts in the PFIC landscape. Advances in molecular genetics and a deeper understanding of bile acid physiology have accelerated the development of targeted pharmacotherapies that directly modulate enterohepatic bile acid circulation. This evolution has expanded options beyond symptom-directed supportive care toward agents that may alter disease trajectory and delay or obviate the need for invasive surgical interventions.

At the same time, clinical practice has begun to embrace more integrated care models that combine specialized hepatology centers, coordinated nutritional support, and earlier referral pathways for transplant evaluation. Regulatory authorities have increasingly offered adaptive pathways and orphan-drug incentives that shorten timelines for therapies addressing ultra-rare diseases, while payers and health systems are refining value frameworks to assess long-term benefits versus upfront costs. The combination of improved diagnostics, a growing pipeline of targeted agents, and evolving reimbursement dialogues has shifted strategic imperatives: sponsors must now plan for differentiated clinical programs, a clear evidence generation strategy for payers, and partnerships with specialty clinics and transplant centers to support adoption and patient monitoring.

Evaluating how United States tariff measures slated for 2025 are poised to affect supply chains, clinical programs, procurement, and patient access for PFIC therapies

Recent tariff actions announced for 2025 within the United States create a new layer of complexity for the PFIC therapeutic ecosystem by affecting the economics and logistics of cross-border supply chains. Many specialized medicines, raw materials, and biologic components rely on international manufacturing and distribution networks. When tariffs increase the landed cost of active pharmaceutical ingredients, finished products, or ancillary devices, sponsors and distributors face pressure to reassess sourcing strategies, inventory practices, and contractual terms with manufacturing partners.

These cost pressures can ripple through procurement practices among hospitals, specialty clinics, and pharmacy channels, compelling tighter negotiations with manufacturers and more stringent evaluation of formulary placements. Clinical development programs are also affected: trial supply budgets, import/export timelines, and site selection may need realignment to maintain continuity of investigational product delivery. In response, stakeholders are prioritizing supply-chain diversification, near-shoring of critical manufacturing steps where feasible, and enhanced demand forecasting to reduce exposure to tariff volatility. Payer engagement strategies must similarly incorporate the implications of higher acquisition costs, focusing on health economic arguments that emphasize downstream reductions in hospitalization or transplantation needs. Overall, the tariff environment underscores the need for strategic planning that minimizes disruption while preserving timely patient access to essential PFIC therapies.

Integrated segmentation intelligence revealing how treatment types, drug classes, care settings, channels, routes, age cohorts, and PFIC subtypes shape strategy and execution

Segment-driven decisioning is essential for tailored development and commercialization in PFIC because the therapeutic journey spans distinct treatment classes, care settings, and patient cohorts. When considering treatment type, pharmacotherapy dominates clinical strategy for disease modification and symptom control, with topical emphasis on bile acid sequestrants and inhibitors of the ileal bile acid transporter as targeted mechanisms. Within pharmacotherapy, bile acid sequestrants such as cholestyramine and colesevelam serve symptomatic and biochemical roles, while IBAT inhibitors-represented by agents like maralixibat and odevixibat-are designed to reduce toxic bile acid accumulation. Complementary options such as rifampicin and ursodeoxycholic acid retain roles in symptom mitigation and biochemical improvement. Supportive care remains foundational, with nutritional support and symptom management critical to maintaining growth and quality of life, while surgical interventions ranging from biliary diversion procedures to liver transplantation provide escalation pathways for refractory or progressive disease.

Drug-class considerations further refine prioritization, with distinctions between antibiotics, sequestrants, IBAT inhibitors, and bile acid modulators influencing clinical trial endpoints, safety monitoring, and commercialization narratives. End-user segmentation highlights the differing needs of homecare environments, hospital inpatient services, and specialty clinic networks, each requiring tailored distribution, education, and adherence support. Distribution-channel choices-including hospital pharmacies, online dispensaries, and retail pharmacies-determine how therapies reach patients and how supply assurance must be managed. Route of administration differentiates products that are oral from those requiring intravenous delivery, shaping adherence strategies and clinical support requirements. Age-group segmentation across children, adolescents, and adults mandates age-appropriate formulations and dosing strategies, while PFIC subtype distinctions among Type I, Type II, and Type III drive molecularly targeted approaches, trial inclusion criteria, and long-term outcome expectations. Synthesizing these segments enables more precise patient identification, clinical pathway design, and go-to-market strategies tailored to the complex realities of PFIC care.

Regional differences in clinical networks, payer frameworks, and healthcare infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access and adoption dynamics

Regional dynamics significantly influence how PFIC therapies are developed, adopted, and reimbursed, with important distinctions across the Americas, Europe Middle East & Africa, and Asia-Pacific that affect clinical practice patterns and access pathways. In the Americas, concentrated centers of excellence, established transplantation networks, and mature specialty pharmacy channels support early adoption of novel therapies, yet payers increasingly demand robust real-world evidence and longitudinal outcomes to justify coverage for high-cost interventions. This environment favors sponsors that can demonstrate clear patient-level benefits and create integrated care pathways involving transplant programs and pediatric hepatology centers.

In Europe Middle East & Africa, fragmented regulatory frameworks and variable reimbursement landscapes require differentiated market access approaches. Nations with centralized health technology assessment bodies emphasize health-economic modeling and comparative-effectiveness evidence, while other jurisdictions may leverage managed access agreements to enable early patient access. Specialty clinics and hospital systems play a vital role in coordinating care and delivering complex interventions. Across the Asia-Pacific region, heterogeneity in healthcare infrastructure, variable access to transplantation, and differing regulatory expectations necessitate flexible clinical and commercial plans. Some markets are accelerating adoption through expanded orphan-disease programs, while others prioritize capacity-building for diagnosis and specialist care. Taken together, regional strategies must account for differences in clinical networks, payer expectations, supply logistics, and the relative maturity of specialty pharmacy channels to achieve effective and equitable access for PFIC patients.

How innovators, specialty manufacturers, and clinical networks are aligning R&D, partnerships, and operational strategies to shape competitive positioning and adoption in PFIC

Company-level dynamics in PFIC combine specialization, strategic partnerships, and adaptive commercialization strategies as essential elements of competitive positioning. Innovators developing targeted agents often partner with clinical centers and academic networks to design trials that capture meaningful endpoints such as pruritus reduction, biochemical improvement, and transplantation-free survival. Specialty pharmaceutical firms and biologic developers differentiate through formulation science, pediatric-friendly administration routes, and data generation plans that address both regulators and payers. Meanwhile, providers and transplant centers increasingly act as strategic partners, supporting registry development, long-term outcome tracking, and coordinated care pathways that facilitate adoption of novel therapies.

Collaborations between manufacturers, contract development and manufacturing organizations, and specialty distributors are also central to maintaining supply continuity for niche therapeutic products. Strategic alliances that enable shared manufacturing capacity, regional distribution hubs, and integrated patient support services reduce time-to-patient and mitigate risks from supply disruptions. Companies that invest in robust post-approval evidence generation-including natural history studies and real-world registries-build stronger value propositions for payers. Finally, competitive strategies that combine clinical differentiation with demonstrable operational readiness, such as patient support programs and clinician education initiatives, tend to accelerate uptake and reinforce long-term position in the PFIC therapeutic space.

Practical, high-impact actions for leaders to align evidence generation, supply resilience, and commercial strategies to accelerate adoption and improve patient outcomes in PFIC

Industry leaders must adopt a coordinated set of actions to ensure that scientific advances in PFIC translate into sustained clinical and commercial impact. First, development programs should prioritize endpoints that reflect meaningful patient experiences and long-term organ preservation, aligning trial designs with payer evidence needs. Sponsors should also invest early in real-world evidence platforms and patient registries that can bridge clinical trial data to long-term outcomes, supporting reimbursement negotiations and post-authorization monitoring.

Operationally, diversifying manufacturing and distribution arrangements will reduce exposure to tariff-induced price pressures and logistical delays, while strategic partnerships with specialty pharmacies and homecare providers will enable more reliable patient access. Commercial strategies must be nuanced for different end users, with tailored educational programs for hospitals and specialty clinics, adherence and support offerings for homecare patients, and streamlined access pathways for retail and online pharmacy channels. Additionally, prioritizing pediatric-friendly formulations and administration routes will support broader adoption across age cohorts. Lastly, fostering closer collaboration with transplant centers and multidisciplinary care teams will ensure that escalation pathways remain fit-for-purpose and that new therapies are integrated into comprehensive care plans that improve patient quality of life and long-term outcomes.

A rigorous mixed-methods approach combining primary stakeholder interviews, clinical literature synthesis, and scenario analysis to validate actionable insights for PFIC stakeholders

This research synthesis is grounded in a multi-method approach designed to integrate clinical expertise, stakeholder perspectives, and evidence from peer-reviewed literature. Primary research included structured interviews with clinicians, transplant surgeons, specialty pharmacists, and payer representatives to capture practical considerations around treatment selection, supply logistics, and reimbursement. These qualitative inputs were triangulated with systematic review of recent clinical literature to identify emerging therapeutic mechanisms, relevant safety considerations, and trial endpoints used in PFIC studies.

Operational and commercial insights were informed by analysis of distribution practices and care-delivery models across hospital, specialty clinic, and homecare settings, along with examination of formulation and route-of-administration constraints that affect adherence and patient experience. Supply-chain implications were assessed through scenario analysis that considered tariff impacts, cross-border manufacturing dependencies, and mitigation strategies such as near-shoring and redundant sourcing. Throughout the process, findings were validated through follow-up consultations with key opinion leaders and clinical program managers to ensure that recommendations are practical, clinically relevant, and aligned with current regulatory and payer expectations. This methodology prioritizes rigor, stakeholder relevance, and applicability to real-world decision-making.

A strategic synthesis highlighting the conditions and collaborative actions required to convert therapeutic innovation into sustainable improvements in PFIC patient outcomes

The PFIC treatment landscape is at an inflection point driven by scientific advances, evolving care models, and shifting economic constraints. Targeted pharmacotherapies that modulate bile acid handling, improvements in clinical networks for multidisciplinary care, and adaptive regulatory pathways collectively create an opportunity to improve outcomes for patients facing progressive cholestatic liver disease. Yet realizing these benefits requires coordinated action: robust evidence generation that speaks to regulators and payers, supply-chain strategies that mitigate external risks, and targeted commercialization plans that reflect the nuances of end-user needs and regional healthcare systems.

Stakeholders who align clinical development with pragmatic operational readiness and payer-centered value demonstration will be best positioned to translate therapeutic potential into measurable patient benefit. Equally important is the cultivation of partnerships across manufacturers, specialty clinics, transplant centers, and patient advocacy networks to ensure that access pathways are equitable and sustainable. If these elements are addressed in concert, the community can move toward earlier intervention, reduced morbidity, and improved long-term outcomes for individuals living with PFIC.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Treatment Type

  • 8.1. Pharmacotherapy
    • 8.1.1. Antibiotics
    • 8.1.2. Bile Acid Sequestrants
      • 8.1.2.1. Cholestyramine
      • 8.1.2.2. Colesevelam
    • 8.1.3. Ibat Inhibitors
      • 8.1.3.1. Maralixibat
      • 8.1.3.2. Odevixibat
    • 8.1.4. Rifampicin
    • 8.1.5. Ursodeoxycholic Acid
  • 8.2. Supportive Care
    • 8.2.1. Nutritional Support
    • 8.2.2. Symptom Management
  • 8.3. Surgical Interventions
    • 8.3.1. Biliary Diversion
    • 8.3.2. Liver Transplantation

9. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Class

  • 9.1. Antibiotics
  • 9.2. Bile Acid Sequestrants
    • 9.2.1. Cholestyramine
    • 9.2.2. Colesevelam
  • 9.3. Ibat Inhibitors
    • 9.3.1. Maralixibat
    • 9.3.2. Odevixibat
  • 9.4. Ursodeoxycholic Acid

10. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Patient Age Group

  • 11.1. Adolescents
  • 11.2. Adults
  • 11.3. Children

12. Progressive Familial Intrahepatic Cholestasis Treatment Market, by PFIC Type

  • 12.1. Type I
  • 12.2. Type II
  • 12.3. Type III

13. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End User

  • 13.1. Homecare
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Progressive Familial Intrahepatic Cholestasis Treatment Market

19. China Progressive Familial Intrahepatic Cholestasis Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie, Inc.
  • 20.6. Albireo Pharma, Inc.
  • 20.7. Alexion Pharmaceuticals, Inc.
  • 20.8. Amgen Inc.
  • 20.9. AstraZeneca PLC
  • 20.10. Biocon Limited
  • 20.11. Boehringer Ingelheim International GmbH
  • 20.12. Bristol-Myers Squibb Company
  • 20.13. Cipla Limited
  • 20.14. Eisai Co., Ltd.
  • 20.15. F. Hoffmann-La Roche Ltd
  • 20.16. Gilead Sciences, Inc.
  • 20.17. Glenmark Pharmaceuticals Limited
  • 20.18. Ipsen Pharma
  • 20.19. Johnson & Johnson
  • 20.20. Merck & Co., Inc.
  • 20.21. Mirum Pharmaceuticals, Inc.
  • 20.22. Novartis International AG
  • 20.23. Par Pharmaceutical Companies, Inc.
  • 20.24. Pfizer Inc.
  • 20.25. Sanofi S.A.
  • 20.26. Takeda Pharmaceutical Company Limited
  • 20.27. Teva Pharmaceutical Industries Ltd.
  • 20.28. Viatris Inc.
  • 20.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC